After several difficult years, the global biotech investment landscape feels materially different.
According to Vision Lifesciences, global biotech VC investment reached approximately $38bn in 2025, up 28% year-on-year and approaching the 2021 peak. Their outlook for 2026 is even more encouraging, with $42–48bn projected. Importantly, this isn't simply more capital. The composition of that capital is changing, with investors showing greater appetite for clinically de-risked assets. Vision Lifesciences’ 2026 Biotech Venture Capital Guide
At the same time, M&A has accelerated. Pharma companies continue to face significant pipeline and patent-cliff pressures, creating strong strategic demand for differentiated biotech assets.
For investors who were burned by clinical failures, falling valuations and the financing environment of 2022–24, the recent wave of exits may also be important psychologically. Returns create confidence, and confidence can create the conditions for capital to be recycled.
The question I find most interesting is where that capital goes next?
For several years, there was a clear preference for later-stage, clinically validated opportunities. Could we now see more capital moving back down the risk curve?
Vision Lifesciences suggests Series A and B activity has already rebounded strongly, while seed and platform-stage funding remains more constrained.
If this continues, 2026 could represent more than a recovery in biotech financing.
It could mark the beginning of a healthier capital cycle, one where successful exits ultimately help fund the next generation of biotech companies.
For those working across global biotech, are you seeing this shift in investor appetite too?